Dendreon Jumps on Analyst Upgrade
Shares of beaten down biotech name Dendreon (NASDAQ: DNDN) are higher during Monday's trading session after the stock was initiated at Needham with a Buy rating. At last check, Dendreon had climbed around 6 percent and was trading at $4.28. This is also where the stock opened the session, so on an intra-day basis, it is flat. Dendreon has struggled mightily in 2012 as sales of its marketed product Provenge have left Wall Street disappointed. Year-to-date, the shares are down nearly 44 percent.
After Monday's jump in its share price, DNDN is now trading a little less than 4 percent above its 20-day moving average. The stock, however, remains 5 percent and 45 percent below its 50-day and 200-day moving averages, respectively.
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.